OREANDA-NEWS. OJSC "VEROPHARM" [RTS:VRPH, MICEX:VFRM] announces its audited financial results for 2012 in accordance with the International Financial Reporting Standards (IFRS).

SALES

Sales for 2012 amounted to RUR 5,507.1 mln. The share of product segments in OJSC “Veropharm” sales is as follows:

Group of pharmaceutical products

Rx drugs sales amounted to RUR 3,678.1 mln. The Rx drugs sales made 66.8% of total sales of the Company;

OTC drugs sales amounted to RUR 791.1 mln. The OTC drugs sales made 14.4% of total sales of the Company.

Traditional drugs sales amounted to RUR 22.3 mln. The traditional drugs sales made 0.4% of total sales of the Company.

Group of non-pharmaceutical products

Non-pharmaceutical products sales made RUR 1,015.5 mln, which corresponds to 18.4% of total sales of the Company.

Under the Federal Reimbursement Program (FRP) Veropharm’s sales amounted to RUR 118.1 mln according to the results of 2012, which corresponds to 2.1% of the Company’s total sales.

The Russian Federation is the main market and ensures 95.1% of the Company's sales. For 2012 the Company exported 4.9% of its products.

PROFIT

In 2012 the gross profit of OJSC “Veropharm” amounted to RUR 3,118 mln. The gross profit ratio for 2012 made 56.6% against 68.1% for 2011. The gross profit ratio of the segments of OJSC “Veropharm” is as stated:

Group of pharmaceutical products

In relation to Rx drugs it made 50.7% in 2012 against 69.3% in 2011;

In relation to OTC drugs it made 71% in 2012 against 73.8% in 2011;

In relation to traditional products it made 52.9% in 2012 against 43.7% in 2011.

Group of non-pharmaceutical products

In relation to non-pharmaceutical products it increased from 59.4% in 2011 to 67% in 2012.

For 2012 EBITDA amounted to RUR 1,588.2 mln. EBITDA margin made 28.8%.

Net profit for the reporting period amounted to RUR 1,163.9 mln.

FACILITIES INVESTMENTS

In 2012 amount of investments assigned for modernization and equipment of the main production facilities of the Company made RUR 1,068.4 mln.

DEBT

As at December 31, 2012 the debt of OJSC “Veropharm” amounted to RUR 1,496.4 mln, which makes no more than 20% of the Company’s net assets value.